Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
Where other types of chips use electricity to stimulate nerves, this one instead tickles cells with minute amounts of chemicals. Because nerve cells normally communicate with each other by releasing chemicals known as neurotransmitters, the new device points to a more effective way of treating very delicate tissues, such as those in the eye and in the brain.
Tissue engineering - already used to build skin and bone - still holds enormous medical potential. The Commission plans to release a comprehensive package of EU rules to govern this promising field.
The proprietary material was originally developed by the Manchester based company to make artificial blood vessels, used to replace diseased arteries which can lead to heart attacks and strokes, and is capable of making significant improvements in surgery for vascular disease.
An MIT team has developed new technology that could jump-start scientists' ability to create specific cell types from human embryonic stem cells, a feat with implications for developing replacement organs and a variety of other tissue engineering applications.
For the first time, UCLA researchers have recreated the ability of mammalian cells to self-organize, forming evenly spaced patterns in a test tube. Published in the June 22, 2004 issue of the Proceedings of the National Academy of Sciences, the findings may help improve methods for regenerating tissue, controlling birth defects and developing new treatments for specific diseases.
A Massachusetts Institute of Technology team has developed new technology that could jump-start scientists' ability to create specific cell types from human embryonic stem cells, a feat with implications for developing replacement organs and a variety of other tissue engineering applications.
Though there has been considerable biological and political debate over the use of embryonic stem cells (ESCs) vs. adult stem cells (ASCs) as therapies for tissue engineering and organ transplants, inherent benefits and drawbacks in both techniques compel them to coexist and complement each other.
CSIRO is mounting a major display of technologies this week at BIO 2004, the world's largest biotechnology conference, being held in San Francisco, USA, from 6-9 June.
A revolutionary type of 'self healing' bandage that uses the patient's own cells is being developed. The technique has already been tried successfully on patients with diabetic ulcers and in the long-term could offer a more effective, quicker and cost efficient way of treating many types of slow-healing wounds such as pressure ulcers.
A breakthrough in polymer development means that soon there may be a radical new treatment for people with broken bones - a special kind of material that can 'glue' the bone back together and support it while it heals. The polmer material is designed to break down as the bone regrows leaving only natural tissue.
Embryonic stem cells may hold the key to regenerating damaged heart muscle, when transplanted within a 3-dimensional scaffold into the infracted heart, according to a new study coming out in June in the Journal of Heart and Lung Transplantation.
Cells derived from the inside of a tooth might someday prove an effective way to treat the brains of people suffering from Parkinson's disease.
Orthonics, Inc., an Atlanta start-up company developing new biomaterials for spinal disc repair and regeneration, has received initial funding from Viscogliosi Brothers, LLC, a New York-based closely held venture capital/private equity and merchant banking firm focused on the musculoskeletal/orthopedics industry. Terms of the funding were not disclosed.
Using technology borrowed from the National Aeronautics and Space Administration (NASA), scientists at the University of Pittsburgh's McGowan Institute for Regenerative Medicine have taken the first steps toward successfully preserving ovarian tissue from rats and mice in culture, including immature egg follicles, according to a study in the current issue of the journal Tissue Engineering.
More than 10 million Americans undergo surgical tooth extractions every year, and the procedure invariably involves some loss of bone from the tooth socket. This bone loss is problematic for dentists because it can compromise both the functional and esthetic outcomes of treatment involving dentures and bridges. Significant losses of bone also make it difficult for surgeons to properly fit dental implants to the ridge of the jawbone without requiring additional surgical procedures.
New treatments for breast cancer, skin and wound healing and obesity will be revealed at an international conference in Cairns, Australia next week.
Eight out of every 1000 children are born with a heart problem. Out of these, every fifth child needs a heart valve. While today’s mechanical or biological heart valves allow children to continue their lives, a research team at RWTH is developing a significantly more compatible heart valve that grows along with the body’s growth.
The University of Missouri Friday announced the discovery of a process to minimize the side effect of painful arthritis that develop after knee surgeries. The procedure will be tested in human clinical trials this summer if the process is approved by the Food and Drug Administration, the Columbia, Mo-based school said.
When biologist Barbara Boyan discovered science’s first proof of biochemical differences between male and female cartilage cells, she began to question the approaches she and other researchers were taking to study cells. Was their thinking biologically relevant?
Pathbreaking developments in tissue engineering and regenerative therapies are facilitating the design and growth of new organs in labs using biopolymer scaffolds and matrices. Analysis of potential markets for tissue engineering reveals that basic problems such as vascularity must be solved before such implants can gain acceptance as standard treatment methods.